Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Flower RJ | Background and discovery of lipocortins. | 1986 | Agents Actions | pmid:2938452 |
Cunha FQ et al. | Failure of PAF-acether to induce in vivo neutrophil migration. | 1988 | Agents Actions | pmid:3055873 |
Etienne A et al. | In vivo inhibition of plasma protein leakage and Salmonella enteritidis-induced mortality in the rat by a specific paf-acether antagonist: BN 52021. | 1986 | Agents Actions | pmid:3515870 |
Mastacchi R et al. | Interaction of a new low molecular weight heparin (OP/LMWH) with human platelets. | 1986 | Agents Actions | pmid:3518359 |
Pettipher ER et al. | PAF-acether in chronic arthritis. | 1987 | Agents Actions | pmid:3630862 |
Wong CW et al. | Comparative effects of tetrandrine and berbamine on subcutaneous air pouch inflammation induced by interleukin-1, tumour necrosis factor and platelet-activating factor. | 1992 | Agents Actions | pmid:1414679 |
Tran A et al. | Separate induction of human blood platelet aggregation or cytotoxicity by different concentrations of PAF-acether and thrombin. | 1992 | Agents Actions | pmid:1414687 |
Okamoto H et al. | Suppression of the Arthus reaction by Y-24180, a potent and specific antagonist of platelet-activating factor. | 1992 | Agents Actions | pmid:1388318 |
Miyagawa H et al. | The effect of WEB 2086 on PAF-induced eosinophil chemotaxis and LTC4 production from eosinophils. | 1992 | Agents Actions | pmid:1456179 |
Ogunbiyi PO and Eyre P | Pharmacological studies of pulmonary anaphylaxis in vitro: a review. | 1985 | Agents Actions | pmid:2420161 |
Lewis AJ et al. | The effects of antiallergic and bronchodilator drugs on platelet-activating factor (PAF-acether) induced bronchospasm and platelet aggregation. | 1984 | Agents Actions | pmid:6152379 |
Kantar A et al. | Effect of PAF on human lymphocyte membranes: a fluorescence study. | 1993 | Agents Actions | pmid:8317302 |
Boonen GJ et al. | Activation of neutrophil migration by dioctanoyl-sn-glycerol and fMet-Leu-Phe is controlled by different pathways. | 1993 | Agents Actions | pmid:8317308 |
Murphy G | Report of the 14th meeting of the British Inflammation Research Association. Topic: cellular and molecular aspects of inflammatory bowel disease. | 1993 | Agents Actions | pmid:8480529 |
Sakamoto T et al. | Effect of beta 2-adrenoceptor agonists against platelet-activating factor-induced airway microvascular leakage and bronchoconstriction in the guinea pig. | 1993 | Agents Actions | pmid:7908496 |
Jouvin-Marche E et al. | Platelet-activating factor (PAF-acether), an activator of neutrophil functions. | 1982 | Agents Actions | pmid:6299078 |
Caillard CG et al. | Hypotensive activity of PAF-acether in rats. | 1982 | Agents Actions | pmid:6299079 |
Czarnetzki BM and Benveniste J | Effect of synthetic PAF-acether on human neutrophil function. | 1981 | Agents Actions | pmid:7041568 |
Camussi G et al. | Neutropenia induced by platelet-activating factor (PAF-acether) released from neutrophils: the inhibitory effect of prostacyclin (PGI2). | 1981 | Agents Actions | pmid:7041569 |
de Bernardis E et al. | Protective effects of papaverine salicylate in mouse ear dermatitis and PAF-induced rat paw oedema. | 1994 | Agents Actions | pmid:7847181 |